tasgh - PowerPoint PPT Presentation

About This Presentation
Title:

tasgh

Description:

tase – PowerPoint PPT presentation

Number of Views:0
Slides: 21
Provided by: gebrena
Category:
Tags:

less

Transcript and Presenter's Notes

Title: tasgh


1
  • Nephrotic/Nephritis Management
  • From Paediatrics ward
  • By Shimelis Engida (PG pharmacy practice
    student)

2
Presentation outlines
  • Introduction
  • Epidemiology
  • Risk factors Aetiology
  • Pathophysiology
  • Clinical presentation
  • Complications
  • Treatment
  • Evaluation and monitoring

3
Introduction
  • The nephrotic syndrome is caused by renal
    diseases that increase the permeability across
    the glomerular filtration barrier.
  • Nephrotic range proteinuria -Urinary protein
    excretion greater than 50 mg/kg per day
  • Hypoalbuminemia - Serum albumin concentration
    less than 3 g/dL (30 g/L)
  • Oedema
  • Hyperlipidaemia

4
Cont..
  • The nephritic syndrome is a clinical syndrome
    that presents as-
  • Haematuria
  • elevated blood pressure
  • decreased urine output, and oedema.
  • The major underlying pathology is inflammation of
    the glomerulus that results in nephritic syndrome

5
Epidemiology
  • As per the final report by the National Center of
    Health Statistics, nephritis syndrome, along with
    nephrotic syndrome, is the 9th leading cause of
    death in the USA in the year 2017.
  • The reported number of combined deaths due to the
    nephritic syndrome, nephrotic syndrome, and renal
    diseases was 50,633 out of a total of 2,813,503
    deaths in the year 2017
  • The mortality rate increases with advancing age.
    The deaths due to nephritic and nephrotic
    syndrome were higher in women, as compared to
    men, per the report.
  • In women, it was the ninth leading cause
    accounting for 1.8 of total deaths, while in
    men, it was not in the top ten causes

6
Risk factors
  • Risk factors of development of minimal change
    disease include1
  • Children within the Age gt1 year but lt8 years
  • Hodgkin lymphoma
  • Leukemia
  • Recent viral illness
  • Toxins such as mercury, gold, bee stings, fire
    coral exposure.
  • Medication such as2
  • Salazopyrin
  • Tiopronin
  • Lithium
  • D-penicillamine
  • Tyrosine-kinase inhibitor

7
Co
  • The following are considered risk factors for the
    development of focal segmental glomerulosclerosis
    (FSGS)
  • Male gender
  • Black race
  • Family history
  • Heroin abuse
  • Drugs known to be associated with FSGS
  • Chronic viral infection
  • Single kidney status
  • Obesity

8
Etiology
  • 90 - are primary glomerular abnormality
  • Other are involvement of other disease (10)
  • We can classify based on etiology
  • Primary
  • Secondary
  • congenital and infantile nephrotic syndrome

9
Conti.....
  • Based on pathological
  • Minimal change disease (MCD)
  • Focal segmental glomerulosclerosis (FSGS)
  • Membranous glomeruli nephropathy
  • Membranoproliferative glomerulonephritis (MPGN)
  • Mesangial proliferation
  • Focal and global glomerulosclerosis

10
CLASSIFICATION
  • Primary nephrotic syndrome, which refers to
    nephrotic syndrome in the absence of an
    identifiable systemic disease.
  • Secondary nephrotic syndrome, which refers to
    nephrotic syndrome in the presence of an
    identifiable systemic disease.
  • Congenital and infantile nephrotic syndrome,
    which occur in children less than one year of age
    and can be either secondary (mostly due to
    infection) or primary.

11
Pathophysiology
  • Damaged glomerular capillary membrane
  • Increase permeability of glomerular capillary
    wall which leads to massive proteinuria, and
    hypoalbuminemia
  • Decrease oncotic pressure
  • Generalized edema
  • Activation of RAAS
  • Sodium retention edema

12
Clinical presentation
  • childhood nephrotic syndrome generally presents
    with oedema
  • periorbital puffiness
  • Ascites
  • Abdominal pain
  • Foaming appearance of urine
  • Weight gain
  • poor appetite

13
Complications
  • Malnutrition
  • Nephrotic edema
  • Infection of NS
  • Thromboembolic complication
  • Lipid abnormality
  • Acute renal failure
  • Chronic kidney disease

14
Treatment
  • Initial treatment of NS in children
  • We recommend that oral glucocorticoids be given
    for 8 weeks (4 weeks of daily glucocorticoids
    followed by 4 weeks of alternate-day
    glucocorticoids) or 12 weeks (6 weeks of daily
    glucocorticoids followed by 6 weeks of
    alternate-day glucocorticoids) (1B)

15
Prevention and treatment of relapses of NS in
children
  • For children with frequently relapsing and
    steroid-dependent nephrotic syndrome
  • who are currently taking alternate-day
    glucocorticoids or are off glucocorticoids, we
    recommend that daily glucocorticoids 0.5 mg/kg/d
    be given during episodes of upper respiratory
    tract and other infections for 57 days to reduce
    the risk of relapse (1C)

16
  • For children with frequently relapsing nephrotic
    syndrome who develop serio glucocorticoid-related
    adverse effects and for all children with
    steroid-dependent nephrotic syndrome
  • we recommend that glucocorticoid-sparing agents
    be prescribed, rather than no treatment or
    continuation with glucocorticoid treatment
  • alone (1B).

17
Steroid-resistant nephrotic syndrome in children
  • We recommend using cyclosporine or tacrolimus as
    initial second-line therapy for children with
    steroid-resistant nephrotic syndrome (1C).

18
(No Transcript)
19
(No Transcript)
20
Reference
  • Heron M. Deaths Leading Causes for 2017. Natl
    Vital Stat Rep. 2019 Jun68(6)1-77. PubMed
Write a Comment
User Comments (0)
About PowerShow.com